The Role of Immunotherapy in Pancreatic Cancer

被引：60

作者：

Mukherji, Reetu ^{[1
]}

Debnath, Dipanjan ^{[2
]}

Hartley, Marion L. ^{[1
]}

Noel, Marcus S. ^{[1
]}

机构：

[1] Medstar Georgetown Univ Hosp, Div Hematol & Oncol, Ruesch Ctr Cure Gastrointestinal Canc, Georgetown Lombardi Comprehens Canc Ctr, 3800 Reservoir Rd NW, Washington, DC 20007 USA

[2] Medstar Washington Hosp Ctr, Dept Internal Med, 110 Irving St NW, Washington, DC 20010 USA

来源：

CURRENT ONCOLOGY | 2022年 / 29卷 / 10期

关键词：

immunotherapy; PD-1; PD-L1; pancreas cancer; adenocarcinoma; checkpoint inhibitor; vaccine; COLONY-STIMULATING FACTOR; CAR T-CELLS; RAS PEPTIDE VACCINATION; SECRETING TUMOR VACCINE; RANDOMIZED PHASE-II; OPEN-LABEL; NAB-PACLITAXEL; GASTROESOPHAGEAL JUNCTION; DUCTAL ADENOCARCINOMA; CHECKPOINT BLOCKADE;

D O I：

10.3390/curroncol29100541

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic adenocarcinoma remains one of the most lethal cancers globally, with a significant need for improved therapeutic options. While the recent breakthroughs of immunotherapy through checkpoint inhibitors have dramatically changed treatment paradigms in other malignancies based on considerable survival benefits, this is not so for pancreatic cancer. Chemotherapies with modest benefits are still the cornerstone of advanced pancreatic cancer treatment. Pancreatic cancers are inherently immune-cold tumors and have been largely refractory to immunotherapies in clinical trials. Understanding and overcoming the current failures of immunotherapy through elucidating resistance mechanisms and developing novel therapeutic approaches are essential to harnessing the potential durable benefits of immune-modulating therapy in pancreatic cancer patients.

引用

页码：6864 / 6892

页数：29

共 166 条

[21]

Buanes T, 2009, J CLIN ONCOL, V27

[22] Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer [J].

Bunt, Stephanie K. ;

Mohr, Ashley M. ;

Bailey, Jennifer M. ;

Grandgenett, Paul M. ;

Hollingsworth, Michael A. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (02) :225-236

[23] DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice [J].

Cao, Jun ;

Jin, Yiqi ;

Li, Wei ;

Zhang, Bin ;

He, Yang ;

Liu, Hongqiang ;

Xia, Ning ;

Wei, Huafeng ;

Yan, Jian .

BMC IMMUNOLOGY, 2013, 14 :1-14

[24] Does detection of microsatellite instability-high (MSI-H) by plasma-based testing predict tumor response to immunotherapy (IO) in patients with pancreatic cancer (PC)? [J].

Chakrabarti, Sakti ;

Bucheit, Leslie A. ;

Starr, Jason S. ;

Innis-Shelton, Racquel ;

Shergill, Ardaman ;

Resta, Regina ;

Wagner, Stephanie Ann ;

Kasi, Pashtoon Murtaza .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)

[25] Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC) [J].

Chen, Inna M. ;

Johansen, Julia S. ;

Theile, Susann ;

Hjaltelin, Jessica X. ;

Novitski, Sif, I ;

Brunak, Soren ;

Hasselby, Jane P. ;

Willemoe, Gro L. ;

Lorentzen, Torben ;

Madsen, Kasper ;

Jensen, Benny, V ;

Wilken, Eva E. ;

Geertsen, Poul ;

Behrens, Claus ;

Nolsoe, Christian ;

Hermann, Kirstine L. ;

Svane, Inge Marie ;

Nielsen, Dorte .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (27) :3180-+

[26] Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition [J].

Cherkassky, Leonid ;

Morello, Aurore ;

Villena-Vargas, Jonathan ;

Feng, Yang ;

Dimitrov, Dimiter S. ;

Jones, David R. ;

Sadelain, Michel ;

Adusumilli, Prasad S. .

JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (08) :3130-3144

[27] Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy. [J].

Chin, Keisho ;

Kato, Ken ;

Cho, Byoung Chul ;

Takahashi, Masanobu ;

Okada, Morihito ;

Lin, Chen-Yuan ;

Kadowaki, Shigenori ;

Ahn, Myung-Ju ;

Hamamoto, Yasuo ;

Doki, Yuichiro ;

Yen, Chueh-Chuan ;

Kubota, Yutaro ;

Kim, Sung-Bae ;

Hsu, Chih-Hung ;

Holtved, Eva ;

Xynos, Ioannis ;

Matsumura, Yasuhiro ;

Takazawa, Akira ;

Kitagawa, Yuko .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)

[28] PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR [J].

Chong, Elise A. ;

Melenhorst, J. Joseph ;

Lacey, Simon F. ;

Ambrose, David E. ;

Gonzalez, Vanessa ;

Levine, Bruce L. ;

June, Carl H. ;

Schuster, Stephen J. .

BLOOD, 2017, 129 (08) :1039-1041

[29] A SU2C catalyst randomized phase II trial of pembrolizumab with or without paricalcitol in patients with stage IV pancreatic cancer who have been placed in best possible response. [J].

Chung, Vincent M. ;

Borazanci, Erkut Hasan ;

Jameson, Gayle S. ;

Evans, Ronald ;

Downes, Michael ;

Truitt, Morgan L. ;

Patel, Hitendra ;

Lowy, Andrew M. ;

Roe, Denise ;

Ansaldo, Karen ;

Barrett, Michael T. ;

Korn, Ronald Lee ;

Caldwell, Lana ;

Slethaug, Gavin ;

Hultsch, Rolf ;

Han, Haiyong ;

Engelthaler, David ;

Pearson, Talima ;

Lenkiewics, Elizabeth ;

Von Hoff, Daniel D. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[30] Dynamics of the immune reaction to pancreatic cancer from inception to invasion [J].

Clark, Carolyn E. ;

Hingorani, Sunil R. ;

Mick, Rosemarie ;

Combs, Chelsea ;

Tuveson, David A. ;

Vonderheide, Robert H. .

CANCER RESEARCH, 2007, 67 (19) :9518-9527

← 1 2 3 4 5 6 7 8 9 10 →